Exercise adherence in a randomized controlled trial of exercise on quality of life in ovarian cancer survivors

Anlan Cao & Leah M. Ferrucci et al. · 2022-12-23

Factors associated with improving exercise in ovarian cancer survivors remain unknown. We explored characteristics associated with exercise adherence among women treated for ovarian cancer in the Women's Activity and Lifestyle Study in Connecticut (WALC) randomized controlled trial. We evaluated adherence among women randomized to the WALC exercise intervention (N = 74). Women had to be exercising ≤ 90 min/week and post-treatment. The intervention included 25 telephone-based exercise counseling sessions over 6 months. Adherence was defined as 150 min/week of moderate/vigorous-intensity exercise. We evaluated factors associated with exercise adherence and duration using multivariate logistic and linear regression. The number of sessions sufficient to achieve 150 min/week was modeled with an unadjusted receiver operating characteristic (ROC) curve. Women were 57.3 ± 8.8 years old and 1.7 ± 1.0 years since diagnosis. The mean exercise time over 6 months was 166.0 ± 66.1 min/week, and 64.9% of women met the 150 min/week goal. Women attended 22.8 ± 3.6 (92%) counseling sessions. No cancer recurrence during the study (OR = 9.15, 95% CI: 1.09-44.02) and greater session attendance (OR = 1.21, 95% CI: 1.02-1.43) were related to meeting the exercise goal. Greater session attendance (P < 0.01) and higher baseline activity level (P = 0.02) were associated with greater average weekly exercise duration. The ROC curve suggested attending 18 counseling sessions was optimal to meet the exercise goal. Women attending more counseling sessions or with no cancer recurrence during the study were more likely to meet the exercise goal. More research is needed to understand ideal counseling intensity for ovarian cancer survivors. Eighteen counseling sessions are sufficient for ovarian cancer survivors to achieve 150 min/week exercise.
Authors
Anlan Cao, Brenda Cartmel, Fang-Yong Li, Linda T. Gottlieb, Maura Harrigan, Jennifer A. Ligibel, Radhika Gogoi, Peter E. Schwartz, Melinda L. Irwin, Leah M. Ferrucci
Funding

NCATS NIH HHS

UL1TR000142

NCI NIH HHS

T32 CA250803

NCATS NIH HHS

UL1 TR000142

NCI NIH HHS

R01 CA138556

NCI NIH HHS

P30 CA016359

National Cancer Institute

NCI 5R01CA138556, P30 CA016359

National Center for Advancing Translational Sciences

UL1TR000142